0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

ω-3 Fatty Acids and Lutein + Zeaxanthin Supplementation for the Prevention of Cardiovascular Disease

Evangelos C. Rizos, MD, PhD1; Evangelia E. Ntzani, MD, PhD2
[+] Author Affiliations
1Department of Internal Medicine and Lipid Disorders Clinic, University Hospital of Ioannina, Ioannina, Greece
2Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
JAMA Intern Med. 2014;174(5):771-772. doi:10.1001/jamainternmed.2013.13734.
Text Size: A A A
Published online

Extract

ω-3 Polyunsaturated fatty acid supplements are increasingly used for the prevention of cardiovascular disease (CVD) either under a physician’s prescription or as over-the-counter products. They currently support a thriving industry with 2011 market sales of $25.42 billion, which grows by more than 15% annually.1 The main effect of ω-3 supplementation is the reduction of triglyceride (TG) levels, whereas additional suggested mechanisms for CVD protection are the prevention of serious arrhythmias, decrease of platelet aggregation, stabilization of atherosclerotic plaque, and reduction of blood pressure.2 Their effect on TG levels is dose dependent, and doses close to 4 g daily can decrease TG level by up to 25%. Although high TG levels have been traditionally considered a secondary target for CVD prevention, they are not incorporated in cardiovascular risk assessment tools. Thus, not surprisingly, the current guidance on ω-3 supplementation for CVD protection is controversial. The latest US guidelines focus on safety of nonstatin treatment and claim that in cases when nonstatin agents must be used, those with reported clinical benefit should be preferred.3 The Food and Drug Administration has approved their administration only as triglyceride-lowering agents for overt hypertriglyceridemia,4 whereas the European Medicines Agency has additionally approved ω-3 supplementation as an adjuvant treatment after myocardial infarction.5

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();